The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Affimed(NASDAQ:AFMD)

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which has completed Phase 2a clinical study of relapsed CD30-...
Website: http://www.affimed.com
Founded: 2000
Full Time Employees: 137
Sector: Healthcare
Industry: Biotechnology
Affimed Days Receivable Outstanding ttm (DSO)
Affimed Op Cashflow Per Share ttm
Affimed Free Cashflow Per Share ttm
Affimed Cash Per Share ttm
Affimed P/S ratio ttm
Affimed (GAAP) P/E ratio ttm
Affimed P/B ratio ttm
No extra charts and metrics for this ticker.